A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2012
At a glance
- Drugs PF 5297909 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- 12 Mar 2012 Actual patient number 51 added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual end date Feb 2012 added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.